Grace Therapeutics, Inc.
General ticker "GRCE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $54.7M (TTM average)
Grace Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -21.4%.
Estimated limits based on current volatility of 1.4%: low 2.32$, high 2.39$
Factors to consider:
- Total employees count: 6 (+50.0%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Clinical trial failure, Regulatory and compliance, Manufacturing risks, Product liability, Inability to raise capital
- Current price 23.3% below estimated low
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2026-03-31 to 2028-03-30
- 2026-03-31 to 2027-03-31 estimated range: [3.04$, 6.28$]
- 2027-03-31 to 2028-03-30 estimated range: [2.60$, 5.52$]
Short-term GRCE quotes
Long-term GRCE plot with estimates
Financial data
| YTD | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $12.85MM | $16.68MM | $11.08MM |
| Operating Income | $-12.85MM | $-16.68MM | $-11.08MM |
| Non-Operating Income | $-1.83MM | $3.91MM | $1.58MM |
| R&D Expense | $6.35MM | $13.54MM | $2.40MM |
| Income(Loss) | $-14.69MM | $-12.77MM | $-9.49MM |
| Taxes | $-1.83MM | $-3.20MM | $-1.70MM |
| Net Income(Loss)* | $-12.85MM | $-9.57MM | $-7.79MM |
| Stockholders Equity | $61.74MM | $66.61MM | $63.90MM |
| Assets | $73.30MM | $71.99MM | $66.65MM |
| Operating Cash Flow | $-12.33MM | $-14.90MM | $-8.87MM |
| Capital expenditure | $0.02MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $0.10MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $7.36MM | $14.03MM | $3.71MM |
| Earnings Per Share** | $-1.35 | $-0.79 | $-0.47 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.